Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | DCAF1 | Q9Y4B6 | 6/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27369965 | 0.90 | MAPK1 (0.38) | MAPK1AURKACDK2DCAF1ROCK2 | |
| SCHEMBL27369980 | 0.85 | MAPK1 (0.38) | MAPK1AURKACDK2DCAF1ROCK2 | |
| SCHEMBL27369934 | 0.85 | DCAF1 (0.48) | MAPK1AURKACDK2DCAF1ROCK2 | |
| SCHEMBL27369968 | 0.80 | MAPK1 (0.35) | MAPK1AURKACDK2DCAF1ROCK2 | |
| SCHEMBL27369957 | 0.78 | MAPK1 (0.39) | MAPK1AURKACDK2DCAF1MAPK3 | |
| SCHEMBL27369904 | 0.78 | DCAF1 (0.51) | MAPK1AURKACDK2DCAF1 | |
| SCHEMBL35212451 | 0.77 | DCAF1 (0.41) | MAPK1AURKACDK2DCAF1 | |
| SCHEMBL35211915 | 0.77 | DCAF1 (0.41) | MAPK1AURKACDK2DCAF1 | |
| SCHEMBL27369938 | 0.75 | MAPK1 (0.42) | MAPK1AURKACDK2DCAF1ROCK2 | |
| SCHEMBL35212428 | 0.74 | DCAF1 (0.43) | MAPK1AURKACDK2DCAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |